The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
CD4+ Count–Guided Interruption of Antiretroviral Treatment
Open accessAbstract
BACKGROUND: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). METHODS: We randomly assigned persons infected with HIV who had a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the viral suppression group) or the episodic use of antiretroviral therapy (the drug conservation group). Episodic use involved the deferral of therapy until the CD4+ count decreased to less than 250 per cubic millimeter and then the use of therapy until the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease. RESULTS: A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral suppression) were followed for an average of 16 months before the protocol was modified for the drug conservation group. At baseline, the median and nadir CD4+ counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per milliliter. Opportunistic disease or death from any cause occurred in 120 participants (3.3 events per 100 person-years) in the drug conservation group and 47 participants (1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardiovascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P=0.007) and 1.7 (95% CI, 1.1 to 2.5; P=0.009), respectively. Adjustment for the latest CD4+ count and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1). CONCLUSIONS: Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antiretroviral therapy, largely as a consequence of lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral therapy does not reduce the risk of adverse events that have been associated with antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Decay characteristics of HIV-1-infected compartments during combination therapy
Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., & Ho, D. D. (1997) · Nature · doi:10.1038/387188a0 · Cited by 1,880
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Cited by
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
Kuller, L. H., Tracy, R., Belloso, W., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050203 · Cited by 1,617
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Self-citationCholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
HIV Infection, Inflammation, Immunosenescence, and Aging
Deeks, S. G. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-042909-093756 · Cited by 1,349
HIV Infection and the Risk of Acute Myocardial Infarction
Freiberg, M. S., Chang, C.-C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., Butt, A. A., Bidwell Goetz, M., Leaf, D., Oursler, K. A., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3728 · Cited by 1,340
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331
“NICMs that are associated with lower nadir CD4 cell count and the simultaneously apparent increased risk of NICM secondary to cumulative exposure to ART [32, 34] has been at least partially resolved by findings from the SMART (Strategies for the Management of Antiretroviral Therapy) study that have shown that HIV infe…”
Result. Plasma levels of soluble CD14 independently predict mortality in HIV infection.
Sandler, N. G., Wand, H., Roque, A., Law, M., Nason, M. C., Nixon, D. E., Pedersen, C., Ruxrungtham, K., Lewin, S. R., Emery, S., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq118 · Cited by 1,106
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Hammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection
Neuhaus, J., Jacobs, Jr., Baker, J. V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L. H., Pett, S. L., Ristola, M., Ross, M. J., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/652749 · Cited by 869
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.
Deeks, S. G., & Phillips, A. N. (2009) · BMJ · doi:10.1136/bmj.a3172 · Cited by 704
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., Post, W. S., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 658
Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study
Hasse, B., Ledergerber, B., Furrer, H., Battegay, M., Hirschel, B., Cavassini, M., Bertisch, B., Bernasconi, E., Weber, R., & Study, T. S. H. C. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir626 · Cited by 608
(2010) · Clinical Infectious Diseases · doi:10.1086/652283 · Cited by 594
Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 582
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals
Duprez, D. A., Neuhaus, J., Kuller, L. H., Tracy, R., Belloso, W., De Wit, S., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044454 · Cited by 520
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Grinspoon, S. K., Fitch, K. V., Zanni, M. V., Fichtenbaum, C. J., Umbleja, T., Aberg, J. A., Overton, E. T., Malvestutto, C. D., Bloomfield, G. S., Currier, J. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304146 · Cited by 502
Aberg, J. A., Gallant, J. E., Ghanem, K. G., Emmanuel, P., Zingman, B. S., & Horberg, M. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit665 · Cited by 496
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Microbial translocation in HIV infection: causes, consequences and treatment opportunities
Sandler, N. G., & Douek, D. C. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2848 · Cited by 472
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 455
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Burdo, T. H., Lo, J., Abbara, S., Wei, J., DeLelys, M. E., Preffer, F., Rosenberg, E. S., Williams, K. C., & Grinspoon, S. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir520 · Cited by 422
HIV Infection and Risk for Incident Pulmonary Diseases in the Combination Antiretroviral Therapy Era
Crothers, K., Huang, L., Goulet, J. L., Goetz, M. B., Brown, S. T., Rodriguez-Barradas, M. C., Oursler, K. K., Rimland, D., Gibert, C. L., Butt, A. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0836oc · Cited by 419
HIV and Inflammation: Mechanisms and Consequences
Hunt, P. W. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0118-8 · Cited by 417
Is HIV a Model of Accelerated or Accentuated Aging?
Pathai, S., Bajillan, H., Landay, A. L., & High, K. P. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt168 · Cited by 414
Kelley, C. F., Kitchen, C. M. R., Hunt, P. W., Rodriguez, B., Hecht, F. M., Kitahata, M., Crane, H. M., Willig, J., Mugavero, M., Saag, M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597093 · Cited by 407
Extended Antiretroviral Prophylaxis to Reduce Breast-Milk HIV-1 Transmission
Kumwenda, N. I., Hoover, D. R., Mofenson, L. M., Thigpen, M. C., Kafulafula, G., Li, Q., Mipando, L., Nkanaunena, K., Mebrahtu, T., Bulterys, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801941 · Cited by 404
Henrich, T. J., Hanhauser, E., Marty, F. M., Sirignano, M. N., Keating, S., Lee, T.-H., Robles, Y. P., Davis, B. T., Li, J. Z., Heisey, A., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-1027 · Cited by 401
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008) · The Journal of Infectious Diseases · doi:10.1086/586713 · Cited by 399
Ray, A. S., Fordyce, M. W., & Hitchcock, M. J. M. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2015.11.009 · Cited by 392
Hsue, P. Y., Hunt, P. W., Schnell, A., Kalapus, S. C., Hoh, R., Ganz, P., Martin, J. N., & Deeks, S. G. (2009) · AIDS · doi:10.1097/qad.0b013e32832b514b · Cited by 388
Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328336a150 · Cited by 384
Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment
Levy, Y., Lacabaratz, C., Weiss, L., Viard, J.-P., Goujard, C., Lelièvre, J.-D., Boué, F., Molina, J.-M., Rouzioux, C., Avettand-Fénoêl, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38052 · Cited by 381
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, J. V., Peng, G., Rapkin, J., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., Cavert, W. P., Henry, W. K., & Neaton, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb76 · Cited by 372
Rodger, A. J., Lodwick, R., Schechter, M., Deeks, S., Amin, J., Gilson, R., Paredes, R., Bakowska, E., Engsig, F. N., & Phillips, A. (2013) · AIDS · doi:10.1097/qad.0b013e32835cae9c · Cited by 372
Currier, J. S., Lundgren, J. D., Carr, A., Klein, D., Sabin, C. A., Sax, P. E., Schouten, J. T., Smieja, M., & for Working Group 2 (2008) · Circulation · doi:10.1161/circulationaha.107.189624 · Cited by 368
Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets
Spearman, C. W., Afihene, M., Ally, R., Apica, B., Awuku, Y., Cunha, L., Dusheiko, G., Gogela, N., Kassianides, C., Kew, M., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30295-9 · Cited by 361
Chow, F. C., Regan, S., Feske, S., Meigs, J. B., Grinspoon, S. K., & Triant, V. A. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31825c7f24 · Cited by 347
Lewden, C., May, T., Rosenthal, E., Burty, C., Bonnet, F., Costagliola, D., Jougla, E., Semaille, C., Morlat, P., Salmon, D., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817efb54 · Cited by 342
Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction
Triant, V. A., Meigs, J. B., & Grinspoon, S. K. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181a9992c · Cited by 338
Associations Between HIV Infection and Subclinical Coronary Atherosclerosis
Post, W. S., Budoff, M., Kingsley, L., Palella, F. J., Witt, M. D., Li, X., George, R. T., Brown, T. T., & Jacobson, L. P. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1754 · Cited by 332
Obel, N., Thomsen, H. F., Kronborg, G., Larsen, C. S., Hildebrandt, P. R., Sorensen, H. T., & Gerstoft, J. (2007) · Clinical Infectious Diseases · doi:10.1086/518285 · Cited by 331
Lo, J., Abbara, S., Shturman, L., Soni, A., Wei, J., Rocha-Filho, J. A., Nasir, K., & Grinspoon, S. K. (2010) · AIDS · doi:10.1097/qad.0b013e328333ea9e · Cited by 323
Ananworanich, J., Schuetz, A., Vandergeeten, C., Sereti, I., de Souza, M., Rerknimitr, R., Dewar, R., Marovich, M., van Griensven, F., Sekaly, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033948 · Cited by 314
Freiberg, M. S., Chang, C.-C. H., Skanderson, M., Patterson, O. V., DuVall, S. L., Brandt, C. A., So-Armah, K. A., Vasan, R. S., Oursler, K. A., Gottdiener, J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0264 · Cited by 313
HIV and cardiovascular disease
So-Armah, K., Benjamin, L. A., Bloomfield, G. S., Feinstein, M. J., Hsue, P., Njuguna, B., & Freiberg, M. S. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30036-9 · Cited by 313
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072375 · Cited by 312
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
HIV and aging: time for a new paradigm.
Justice, A. C. (2010) · Current HIV/AIDS Reports · doi:10.1007/s11904-010-0041-9 · Cited by 309
Grunfeld, C., Delaney, J. A., Wanke, C., Currier, J. S., Scherzer, R., Biggs, M. L., Tien, P. C., Shlipak, M. G., Sidney, S., Polak, J. F., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832d3b85 · Cited by 309
Gross, A. M., Jaeger, P. A., Kreisberg, J. F., Licon, K., Jepsen, K. L., Khosroheidari, M., Morsey, B. M., Swindells, S., Shen, H., Ng, C. T., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.019 · Cited by 306
Lang, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.197 · Cited by 306
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
Cohen, M. S., Hellmann, N., Levy, J. A., DeCock, K., & Lange, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34706 · Cited by 304
Torriani, F. J., Komarow, L., Parker, R. A., Cotter, B. R., Currier, J. S., Dubé, M. P., Fichtenbaum, C. J., Gerschenson, M., Mitchell, C. K. C., Murphy, R. L., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.049 · Cited by 300
Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., Boccara, F., Bingham, A., & Costagliola, D. (2010) · AIDS · doi:10.1097/qad.0b013e328339192f · Cited by 299
Low CD4+T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study
Lichtenstein, K. A., Armon, C., Buchacz, K., Chmiel, J. S., Buckner, K., Tedaldi, E. M., Wood, K., Holmberg, S. D., & Brooks, J. T. (2010) · Clinical Infectious Diseases · doi:10.1086/655144 · Cited by 296
HIV-1 DNA predicts disease progression and post-treatment virological control
Williams, J. P., Hurst, J., Stöhr, W., Robinson, N., Brown, H., Fisher, M., Kinloch, S., Cooper, D., Schechter, M., Tambussi, G., et al. (2014) · eLife · doi:10.7554/elife.03821 · Cited by 293
Accessing Antiretroviral Therapy Following Release From Prison
Baillargeon, J. (2009) · JAMA · doi:10.1001/jama.2009.202 · Cited by 289
T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women
Kaplan, R. C., Sinclair, E., Landay, A. L., Lurain, N., Sharrett, A. R., Gange, S. J., Xue, X., Hunt, P., Karim, R., Kern, D. M., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq071 · Cited by 289
HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment
Edén, A., Fuchs, D., Hagberg, L., Nilsson, S., Spudich, S., Svennerholm, B., Price, R. W., & Gisslén, M. (2010) · The Journal of Infectious Diseases · doi:10.1086/657342 · Cited by 286
Lifson, A. R., Neuhaus, J., Arribas, J. R., van den Berg-Wolf, M., Labriola, A. M., Read, T. R. H., & for the INSIGHT SMART Study Group (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.188664 · Cited by 281
Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe
Mocroft, A., Reiss, P., Gasiorowski, J., Ledergerber, B., Kowalska, J., Chiesi, A., Gatell, J., Rakhmanova, A., Johnson, M., Kirk, O., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181e9be6b · Cited by 274
The role of HIV in serious diseases other than AIDS.
Phillips, A. N., Neaton, J., & Lundgren, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3283174636 · Cited by 269
Sudden Cardiac Death in Patients With Human Immunodeficiency Virus Infection
Tseng, Z. H., Secemsky, E. A., Dowdy, D., Vittinghoff, E., Moyers, B., Wong, J. K., Havlir, D. V., & Hsue, P. Y. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.024 · Cited by 269
Universal Voluntary Testing and Treatment for Prevention of HIV Transmission
Dieffenbach, C. W. (2009) · JAMA · doi:10.1001/jama.2009.828 · Cited by 269
Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults
Hsue, P. Y., Deeks, S. G., & Hunt, P. W. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis200 · Cited by 269
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men
Kaplan, R. C., Kingsley, L. A., Gange, S. J., Benning, L., Jacobson, L. P., Lazar, J., Anastos, K., Tien, P. C., Sharrett, A. R., & Hodis, H. N. (2008) · AIDS · doi:10.1097/qad.0b013e328300581d · Cited by 265
Armah, K. A., McGinnis, K., Baker, J., Gibert, C., Butt, A. A., Bryant, K. J., Goetz, M., Tracy, R., Oursler, K. K., Rimland, D., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis406 · Cited by 262
HIV and Coronary Heart Disease
Boccara, F., Lang, S., Meuleman, C., Ederhy, S., Mary-Krause, M., Costagliola, D., Capeau, J., & Cohen, A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.063 · Cited by 262
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
Mitsuyasu, R. T., Merigan, T. C., Carr, A., Zack, J. A., Winters, M. A., Workman, C., Bloch, M., Lalezari, J., Becker, S., Thornton, L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1932 · Cited by 261
Mocroft, A., Phillips, A., Gatell, J., Ledergerber, B., Fisher, M., Clumeck, N., Losso, M., Lazzarin, A., Fatkenheuer, G., & Lundgren, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60948-9 · Cited by 259
Tseng, A., Seet, J., & Phillips, E. J. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12403 · Cited by 256
Santos, G.-M., Ackerman, B., Rao, A., Wallach, S., Ayala, G., Lamontage, E., Garner, A., Holloway, I. W., Arreola, S., Silenzio, V., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-020-02969-0 · Cited by 253
The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden, C., Bouteloup, V., De Wit, S., Sabin, C., Mocroft, A., Wasmuth, J. C., van Sighem, A., Kirk, O., Obel, N., et al. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr164 · Cited by 252
HIV infection and cardiovascular disease
Hemkens, L. G., & Bucher, H. C. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht528 · Cited by 251
The Mind Exchange Working Group, Antinori, A., Arendt, G., Grant, I., Letendre, S., Chair, Munoz-Moreno, J. A., Eggers, C., Brew, B., Brouillette, M.-J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis975 · Cited by 208
. Towards a combined prognostic index for survival in HIV infection: the role of non-HIV biomarkers.
Justice, A., McGinnis, K., Skanderson, M., Chang, C., Gibert, C., Goetz, M., Rimland, D., Rodriguez‐Barradas, M., Oursler, K., Brown, S., et al. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2009.00757.x · Cited by 159
Strom, B. L., Eng, S. M., Faich, G., Reynolds, R. F., D'Agostino, R. B., Ruskin, J., & Kane, J. M. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.08040484 · Cited by 122
Hamlyn, E., Ewings, F. M., Porter, K., Cooper, D. A., Tambussi, G., Schechter, M., Pedersen, C., Okulicz, J. F., McClure, M., Babiker, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043754 · Cited by 71
Edwards-Jackson, N., Kerr, S., Tieu, H., Ananworanich, J., Hammer, S., Ruxrungtham, K., Phanuphak, P., Avihingsanon, A., & for the HIV-NAT 006 Study Team (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00916.x · Cited by 53
Chou, R., Selph, S., Dana, T., Bougatsos, C., Zakher, B., Blazina, I., & Korthuis, P. T. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00007 · Cited by 46
Cardiovascular disease risk in an aging HIV population: not just a question of biology
So-Armah, K., & Freiberg, M. S. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000065 · Cited by 45
Harries, A. D., Ford, N., Jahn, A., Schouten, E. J., Libamba, E., Chimbwandira, F., & Maher, D. (2016) · BMC Public Health · doi:10.1186/s12889-016-3620-x · Cited by 42
Primary HIV infection: clinical presentation, testing, and treatment.
Henn, A., Flateau, C., & Gallien, S. (2017) · Current Infectious Disease Reports · doi:10.1007/s11908-017-0588-3 · Cited by 34
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2283-2296
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1497170016
- Cited by
- 2,231
- References
- 33
- FWCI
- 91.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.